Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

nonsteroidal anti-inflammatory drugs, or corticosteroids. The most common adverse reactions reported in ≥5% with LEQEMBI and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo ...